$QURE

Jacques Rachelle Suzanne sold $54K of QURE

Jacques Rachelle Suzanne sold 1,993 shares of uniQure N.V. (QURE) at $27.06 on 2026-06-11.

Original reporting
SEC EDGAR · Jacques Rachelle Suzanne
Published Jun 12, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Neutral
high confidence
Mentioned
$QURE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details (shares, price, total value, post-transaction holdings). No company-specific catalyst is included.

02

Market read

Traders may note the insider sale, but without additional company news it is unlikely to materially reset valuation or risk.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the article provides no context for motive or whether other insiders are selling/buying concurrently.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-12; sale executed 2026-06-11.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QURENeutralHigh confidence
Context

uniQure director Jacques Rachelle Suzanne sold 1,993 shares in an open-market transaction on 2026-06-11 at $27.06/share (Form 4).

Expected impact

Low near-term impact; any effect is likely short-lived unless followed by additional insider activity or company-specific catalysts.

Evidence & confidence

The filing is a standard director open-market sale with no 10b5-1 plan and no accompanying company event (earnings, guidance, deal, or regulatory action) in the text.

Market effects

No clear sector read-through; this is a single-company insider transaction with no disclosed operational/regulatory change.

None indicated.

None indicated.

Counterpoint

Absence of a stated 10b5-1 plan could be interpreted by some traders as less “mechanical,” potentially increasing short-term skepticism.

Key entities

  • uniQure N.V.

    Subject of the Form 4 insider transaction disclosure.

  • Jacques Rachelle Suzanne

    Director who sold 1,993 shares on 2026-06-11.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.